Niraparib Indications in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Niraparib is FDA-approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response (CR/PR) to first-line platinum-based chemotherapy, regardless of BRCA mutation or homologous recombination deficiency (HRD) status. 1
FDA-Approved Indications
First-Line Maintenance Therapy
- Patient Population: Adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Timing: Following first-line platinum-based chemotherapy
- Response Required: Complete response (CR) or partial response (PR)
- Mutation Status: No BRCA mutation or HRD testing required for this indication 1
Recurrent Disease Setting
Niraparib is also approved for treatment (not just maintenance) of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have:
- Been treated with ≥3 prior chemotherapy regimens
- HRD-positive status (defined by deleterious/suspected deleterious BRCA mutation OR genomic instability)
- Progressed >6 months after response to last platinum-based chemotherapy 1
Clinical Context and Evidence
PRIMA Trial Support
The NCCN Guidelines designate niraparib as a Category 1 recommendation for patients with Stage II-IV disease with BRCA mutations who achieve CR/PR after first-line platinum-based chemotherapy, based on the PRIMA trial 1. For patients with BRCA wild-type or unknown status, niraparib remains a Category 2A recommendation 1.
Key Efficacy Data
In the PRIMA trial, niraparib demonstrated:
- HRD population: Median PFS of 21.9 months vs 10.4 months with placebo (P<0.001)
- Overall population: Median PFS of 13.8 months vs 8.2 months with placebo (P<0.001)
- HRP population: Median PFS of 8.4 months vs 5.4 months with placebo 2, 3
Companion Diagnostic Requirement
Important: Patients should be selected for therapy based on an FDA-approved companion diagnostic for niraparib 1. This is particularly relevant for the recurrent disease indication requiring HRD-positive status.
Dosing Considerations
The individualized starting dose (ISD) strategy is recommended:
- 300 mg daily (3 × 100-mg capsules): For patients with baseline body weight ≥77 kg AND baseline platelet count ≥150,000/μL
- 200 mg daily (2 × 100-mg capsules): For patients with baseline body weight <77 kg OR baseline platelet count <150,000/μL 4
This dosing strategy has been shown to reduce hematologic toxicities while maintaining efficacy 5.
Common Pitfalls and Caveats
Timing of Initiation: Patients must be randomized/started within 12 weeks of the first day of the last cycle of chemotherapy 4. Delays beyond this window may compromise eligibility.
Prior Bevacizumab Use: After first-line therapy with bevacizumab, data are limited on maintenance with single-agent niraparib. However, based on the magnitude of benefit in other subgroups, single-agent niraparib can be considered 1. The combination of olaparib + bevacizumab may be preferred in this setting for patients with BRCA mutations or HRD 1.
Toxicity Management: Hematologic toxicities (thrombocytopenia, anemia, neutropenia) are the most common grade 3-4 adverse events 3, 6. Most adverse events occur during initial months and are manageable with dose interruptions or reductions 7, 5. Dose adjustments were required in 56% of real-world patients, primarily for hematologic toxicities 5.
No OS Benefit Demonstrated: The final PRIMA analysis showed no difference in overall survival between niraparib and placebo arms, likely because approximately 50% of placebo patients received a PARP inhibitor in subsequent lines 2. Treatment decisions should focus on PFS benefit and quality of life considerations.